Navigating FDA: Mfg, Inspections & Supply Chain

Change has been the operative word at FDA not only in leadership but in new policy initiatives impacting manufacturing, the inspection process, and the supply chain. An upcoming DCAT webinar sums up the latest.

Change has been the operative word at FDA not only in leadership but in new policy initiatives impacting manufacturing, the inspection process, and the supply chain. An upcoming DCAT webinar sums up the latest.

An executive briefing
Effective supply planning in the bio/pharmaceutical industry requires recognizing, responding, and mitigating supplier, geopolitical and business risks to build resilient and robust supply chains for supply assurance. Part of that calculus involves adaptability to changing regulatory requirements: so what were the policies in 2026 that mattered the most, and what should be on the industry’s radar in 2027?

Carolyn Dorgan 
Vice President, Solution Engineering 
Suttons Creek 

The webinar, Navigating FDA: Manufacturing, Inspections, and the Supply Chain, will provide an executive briefing of the key policy initiatives and actions taken by FDA in 2026 impacting manufacturing, the inspection process, and the supply chain. The webinar, which is exclusive and complimentary to DCAT Member Companies, will be Thursday December 3, 2026, 10:00-10:30 AM ET, with on-demand viewing available post-webinar to registrants. Further information, including how to register, may be found here.

Jennifer Krolikowski 
Director, Strategic Programs, Biologics Sourcing & Procurement 
Merck 

Providing that overview will be Carolyn Dorgan, Vice President, Solution Engineering, Suttons Creek, a consultancy serving the bio/pharmaceuticals industry. She is an influential and adaptive leader with 15+ years of experience spanning the US Food and Drug Administration and the biologics, medical device and combination product industries. In her role at the firm, she leads cross-functional teams and guides clients through complex regulatory, quality, and organizational challenges—driving alignment and action across diverse functions and cultures. Previously, she served in various leadership roles at FDA, where she led the Infusion Devices team and shaped international standards for drug delivery, injection systems, and pediatric medical devices. She is recognized globally as an authority in combination product development, frequently speaking at international conferences and contributing to over a dozen standards & guidance documents.

The webinar was developed by the volunteer DCAT Supply Management Committee composed of senior to mid-level executives from DCAT Member Companies involved in sourcing, procurement, and supply management. Jennifer Krolikowski, Director, Strategic Programs, Biologics Sourcing & Procurement at Merck and Chair of the DCAT Supply Management Committee, will moderate the webinar.  

Recent Feature Articles

Incentivizing US-Based Contract Biomanufacturing 

By
The Biotechnology Innovation Organization (BIO) is recommending a seven-point action plan to increase US competitiveness in biotech, including incentives for increasing US-based contract biomanufacturing.

The Next Round in the Obesity Drug Market 

By
Pfizer’s move to secure $1.5 billion in funding from the investment firm, Blackstone, to advance its late-stage GLP-1 candidate is heating up the obesity drug market. A look at the revenue leaders and contenders.

CDMO Moves: Lonza Increasing Position in US

By
Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?

Orphan Drugs: The Top Products & Companies

By
Orphan drug sales are projected to reach a peak of 30% of the global prescription drug market by 2027 and sales of $400 billion by 2032. What products and companies are leading growth?